In localised prostate cancer management, the ProtecT trial compared active monitoring, radical prostatectomy, and radiotherapy. The primary finding at 10 years regarding prostate cancer-specific mortality was:

• A Radical prostatectomy had significantly lower cancer-specific mortality than radiotherapy
• B Active monitoring led to significantly higher metastatic progression
• C All three groups had similar low prostate cancer-specific mortality (~1%) ✓
• D Radiotherapy had significantly higher biochemical recurrence than surgery

Explanation

The ProtecT trial at 10 years showed that prostate cancer-specific mortality was very low and similar across all three groups (~1%), regardless of treatment modality. However, active monitoring was associated with higher rates of metastasis and disease progression compared to intervention groups. This highlighted that low PSA-detected localised prostate cancer has excellent short-to-medium-term prognosis regardless of initial treatment choice.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.